Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Operations (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Cash from Operations for 8 consecutive years, with 16227000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 5613.73% year-over-year to 16227000.0, compared with a TTM value of 74271000.0 through Dec 2025, down 24.31%, and an annual FY2025 reading of 74271000.0, down 24.31% over the prior year.
  • Cash from Operations was 16227000.0 for Q4 2025 at Arcturus Therapeutics Holdings, up from 17151000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 160259000.0 in Q4 2022 and bottomed at 49039000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 12758350.0, with a median of 26953000.0 recorded in 2024.
  • The sharpest move saw Cash from Operations skyrocketed 477.11% in 2022, then crashed 5613.73% in 2025.
  • Year by year, Cash from Operations stood at 42497000.0 in 2021, then surged by 477.11% to 160259000.0 in 2022, then tumbled by 100.39% to 629000.0 in 2023, then surged by 54.85% to 284000.0 in 2024, then plummeted by 5613.73% to 16227000.0 in 2025.
  • Business Quant data shows Cash from Operations for ARCT at 16227000.0 in Q4 2025, 17151000.0 in Q3 2025, and 5755000.0 in Q2 2025.